Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lipella PharmaceuticalsLIPO -49.38% EV-to-EBITDA is 0.27 as of Jul. 23, 2026. The stock has 1 warning sign investors should review. Among 400 Biotechnology companies, Lipella Pharmaceuticals ranks better than 89.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Lipella Pharmaceuticals's enterprise value is $-1.44 Mil.
Lipella Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-5.34 Mil. Therefore, Lipella Pharmaceuticals's EV-to-EBITDA for today is 0.27.
The historical rank and industry rank for Lipella Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
LIPO'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.87 Med: -0.48 Max: 0.46
Current: 0.27
During the past 5 years, the highest EV-to-EBITDA of Lipella Pharmaceuticals was 0.46. The lowest was -8.87. And the median was -0.48.
LIPO's EV-to-EBITDA is ranked better than 89.75% of 400
companies
in the Biotechnology industry
Industry Median: 12.15
vs LIPO: 0.27
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Lipella Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Lipella Pharmaceuticals's share price for today is $0.0327.
Lipella Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIPO vs IOBTQ, WINT, CYTOF: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's EV-to-EBITDA falls into.
Lipella Pharmaceuticals's current Enterprise Value is $-1.44 Mil.
Lipella Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lipella Pharmaceuticals (LIPO) has a EV-to-EBITDA of 0.27 as of Jul. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lipella Pharmaceuticals. According to the industry distribution chart, Lipella Pharmaceuticals ranks #41 out of 400 companies in the Biotechnology industry, placing it in the top 10.2%.
Is Lipella Pharmaceuticals' EV-to-EBITDA too high?
Lipella Pharmaceuticals' current EV-to-EBITDA is 0.27. The Biotechnology industry median EV-to-EBITDA is 12.15. Lipella Pharmaceuticals' value of 0.27 is 97.8% below this industry median. Based on the distribution chart, Lipella Pharmaceuticals ranks #41 out of 400 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Lipella Pharmaceuticals' EV-to-EBITDA compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #41 out of 400 companies for EV-to-EBITDA. This places Lipella Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.15. Lipella Pharmaceuticals' value of 0.27 is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.15, based on 400 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lipella Pharmaceuticals's current EV-to-EBITDA of 0.27 is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Lipella Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 12.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lipella Pharmaceuticals's current EV-to-EBITDA is 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.74, compared to a current price of $0.03 — trading 99.6% below its estimated fair value. The current EV-to-EBITDA is 0.27 and 97.8% below the Biotechnology industry median of 12.15. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current EV-to-EBITDA is 0.27 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
